VA-NEUSTAR-INC.
13.10.2021 09:02:08 CEST | Business Wire | Press release
Neustar Inc., a global information services and technology company and leader in identity resolution, today announces the redesign of the company’s Partner Program, renamed ‘Ultra Secure Partner Program’ (USPP). Providing enhanced channel access to its unmatched range of cloud-based security solutions, globally distributed network, and mature family of security services, partners can now easily curate and grow their cloud security portfolios.
In addition, Neustar Security Solutions also announces the appointment of Jeremy Nicholls as Vice President of Global Channels. The move comes as part of a wider effort to further grow the company’s channel business.
Ahead of joining Neustar in January 2021, Jeremy was Vice President of Global Channels & Alliances at Arbor Networks for 9 years. He has also held channel and direct sales leadership roles at Niksun, Polycom, and Ericsson and holds an MBA from Bath University in the UK.
Ultra Secure Partner Program
The newly designed program provides a clearly defined tiered structure for its partners to operate within, ensuring clarity on expectations from both parties, with consistent practices, policies, and discounts. Now a standardized, tiered program, the USPP offers varying benefits and expectations to partners depending upon the commitment made, with benefits increasing in higher tiers.
Higher levels of partnership have benefits including, but not limited to: higher discounting, qualified sales leads, training and support, account mapping, access to Neustar specialists and expertise, and focused marketing support, such as promotional materials, customizable collateral, special program funding, and case studies, to help partners generate more business. Discounts offered throughout the program have been increased to afford leading margins to partners, with rates varying by partner tier and reflective of partner engagement levels.
“We’ve reimagined Neustar Security Solutions’ partner program to make it as compelling as possible. Now a simple and value-driven program based on partner engagement levels, we offer highly competitive margins and unrivalled support to our partners ,” said Jeremy Nicholls. “As the world continues to move to the cloud, Neustar Security Solutions is uniquely positioned to partner with organisations who want to grow existing, and secure new customers based around cloud security, where they can wrap their own incremental services to the offerings. ”
Ed Lorenzini, CEO, Analyze Corporation said: “Neustar Security Solutions is a trusted partner of Analyze Corporation. This revamped and standardised program makes growing our business easier and even more rewarding. By participating in Neustar’s USPP, we are able to provide our customers with world-leading security solutions, support and insights that map to their cloud needs.”
Güngör Gündoğdu, Managing Director, Inforte added: “In this growing landscape, we at Inforte have found a valued partner in Neustar Security Solutions. By participating in Neustar’s USPP, our work together is smooth and straightforward, from customer registration through to delivery.”
The new channel partner programs are specifically targeted to expand sales and support coverage for Neustar Security Solutions in the United States, Canada, and Europe, with additional opportunities in Latin America and Eastern Europe.
For more information about the program, visit https://www.home.neustar/about-us/partners/security-partners or contact partners@team.neustar for a direct engagement.
About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, and Security that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom